Overview
IRD market data
Price History
IRD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -892.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.04 – $5.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $304.5M · P/B 9.03 · P/S 25.41.
Company News
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9Benzinga · Aug 7, 2026, 8:00 PM
Opus Genetics Files Prospectus To Sell $300M Mixed Securities Shelf Including 34.5M SharesBenzinga · Aug 7, 2026, 10:33 AM
Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M EstimateBenzinga · Aug 6, 2026, 11:29 AM
8-K filing — Opus Genetics, Inc. (IRD)SEC EDGAR · Aug 6, 2026, 11:04 AM
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal DiseaseBenzinga · Aug 3, 2026, 11:06 AM
TD Cowen Initiates Coverage On Opus Genetics with Buy RatingBenzinga · Jul 29, 2026, 2:28 PM
Top 3 Health Care Stocks That May Rocket Higher In JulyBenzinga · Jul 20, 2026, 10:03 AM
Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026Benzinga · Jul 9, 2026, 11:10 AM
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price TargetBenzinga · Jul 6, 2026, 4:55 PM
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseGlobenewswire Inc · Jul 6, 2026, 11:15 AM